Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTC4S | Q16873 | 5/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2768751 | 0.80 | CFTR (0.33) | LTC4S | |
| SCHEMBL2768795 | 0.76 | LTC4S (0.31) | LTC4S | |
| SCHEMBL2768179 | 0.76 | — | — | |
| SCHEMBL2768177 | 0.76 | — | — | |
| SCHEMBL28906595 | 0.76 | KDM4E (0.36) | POLB | |
| SCHEMBL5078801 | 0.75 | — | — | |
| SCHEMBL14909257 | 0.72 | PIK3CA (0.35) | — | |
| SCHEMBL2768497 | 0.72 | KEAP1 (0.64) | KEAP1NFE2L2POLB | |
| SCHEMBL28906545 | 0.70 | SMN1; SMN2 (0.41) | KEAP1NFE2L2POLB | |
| SCHEMBL3770744 | 0.69 | LMNA (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184751-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | BALLELL-PAGES LLUIS | 2010-07-22 | — | — | US | disclosed |
| US-7732460-B2 | Heterocyclic compounds, their preparation and their use as antibacterials | GLAXO GROUP LIMITED (GB) | 2010-06-08 | — | — | US | disclosed |
| US-20100137353-A1 | TRICYCLIC COMPOUNDS AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| EP-1963324-B1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LTD (GB) | 2010-04-21 | — | — | EP | disclosed |
| US-20090036433-A1 | Heterocyclic Compounds, their Preparation and their Use as Antibacterials | GLAXO GROUP LIMITED (GB) | 2009-02-05 | — | — | US | disclosed |
| EP-2005995-A1 | Heterocyclic compounds for the treatment of tuberculosis | GLAXO GROUP LIMITED (GB) | 2008-12-24 | — | — | EP | disclosed |
| EP-1963324-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2008-09-03 | — | — | EP | disclosed |
| US-20070185153-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| WO-2007071936-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185153-A1 | COMPOUNDS | NRDC, NISCH, MRPL21 | LTC4S 599/4885KEAP1 1666/4885NFE2L2 952/4885 |
| US-20100137353-A1 | TRICYCLIC COMPOUNDS AS ANTIBACTERIALS | NRDC, NACA, NOP2 | LTC4S 1034/4885KEAP1 3292/4885NFE2L2 2043/4885 |
| US-20100184751-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | SDHA, SDHB, NNT | LTC4S 129/4885KEAP1 1345/4885NFE2L2 743/4885 |
| US-20090036433-A1 | Heterocyclic Compounds, their Preparation and their Use as Antibacterials | MRPL21, NACA, NISCH | LTC4S 1091/4885KEAP1 1880/4885NFE2L2 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.